Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS)

ClinicalTrials.gov ID: NCT03222973

Public ClinicalTrials.gov record NCT03222973. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 4:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With Optional Open-Label Extension in Subjects With Relapsing Multiple Sclerosis to Evaluate the Efficacy and Safety of BIIB033 as an Add-On Therapy to Anti-Inflammatory Disease-Modifying Therapies

Study identification

NCT ID
NCT03222973
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Biogen
Industry
Enrollment
263 participants

Conditions and interventions

Interventions

  • BIIB033 (opicinumab) Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 58 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 14, 2017
Primary completion
Feb 11, 2021
Completion
Feb 11, 2021
Last update posted
Apr 27, 2022

2017 – 2021

United States locations

U.S. sites
51
U.S. states
28
U.S. cities
47
Facility City State ZIP Site status
Research Site Cullman Alabama 35058
Research Site Gilbert Arizona 85234
Research Site Berkeley California 94705
Research Site Long Beach California 90806
Research Site Newport Beach California 92663
Research Site Orange California 92868
Research Site Centennial Colorado 80112
Research Site Fort Collins Colorado 80528
Research Site Stamford Connecticut 06905
Research Site Washington D.C. District of Columbia 20007
Research Site Sunrise Florida 33351
Research Site Tampa Florida 33612
Research Site Atlanta Georgia 30309
Research Site Chicago Illinois 60612
Research Site Chicago Illinois 60637
Research Site Overland Park Kansas 66212
Research Site Lexington Kentucky 40513
Research Site Baltimore Maryland 21287
Research Site Boston Massachusetts 02114
Research Site Boston Massachusetts 02215
Research Site Lexington Massachusetts 01805
Research Site Wellesley Massachusetts 02481
Research Site Farmington Hills Michigan 48334
Research Site Minneapolis Minnesota 55422
Research Site St Louis Missouri 63110
Research Site St Louis Missouri 63131
Research Site Las Vegas Nevada 89106
Research Site Freehold New Jersey 07728
Research Site Teaneck New Jersey 07666
Research Site Latham New York 12110
Research Site New York New York 10021
Research Site Patchogue New York 11772
Research Site Rochester New York 14642
Research Site Stony Brook New York 11794
Research Site Durham North Carolina 27710
Research Site Raleigh North Carolina 27607
Research Site Columbus Ohio 43214
Research Site Dayton Ohio 45417
Research Site Oklahoma City Oklahoma 73104
Research Site Portland Oregon 97225
Research Site Pittsburgh Pennsylvania 15213
Research Site Willow Grove Pennsylvania 19090
Research Site Knoxville Tennessee 37922
Research Site Memphis Tennessee 38018
Research Site Dallas Texas 75390-8806
Research Site Houston Texas 77030
Research Site Round Rock Texas 78681
Research Site Orem Utah 84058
Research Site Salt Lake City Utah 84103
Research Site Seattle Washington 98122
Research Site Seattle Washington 98133

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 108 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03222973, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 27, 2022 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03222973 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →